Fibromyalgia is a long-term condition defined primarily by chronic widespread pain. It does not show up on a blood test, an X-ray, a standard neurological examination, or any routine imaging, which has made it one of the more contested diagnoses in modern medicine. Strictly, signs are what a clinician observes; symptoms are what a patient reports. Fibromyalgia has few measurable signs, which is partly why its history is so disputed. The question was once whether the condition existed at all. The better question now is which of the proposed explanations for it can be supported by the available research.
Estimates of prevalence shift with the diagnostic criteria used and the population studied. The US Centers for Disease Control and Prevention places the figure at around 4 million adults, roughly 2 percent of the adult population. Women receive the diagnosis more often than men, but the ratio is heavily influenced by how the condition is defined.
Signs that usually arrive first
Most patients do not begin with a single symptom. The typical presentation is a cluster of pain that has lasted for at least three months, fatigue that sleep does not fix, a mind that feels slower than it used to, and stiffness that lingers after rest. Muscle stiffness after rest is common, as are headaches and abdominal discomfort. None of these alone points to fibromyalgia; together they often do.
The pain is usually described as aching, burning, deep, or strangely electric, and it appears on both sides of the body above and below the waist. Patients may move from one specialist to another before the pieces are assembled, and the delay between first symptom and diagnosis can run into years.
The diagnostic problem
For years, diagnosis depended on counting tender points. A physician pressed eighteen specified spots, and if eleven hurt, the criteria were met. The method looked objective; it was not particularly reproducible. A test that requires eleven tender points is as much a test of the examiner's thumbs as of the patient's pain.
Since 2010, the American College of Rheumatology criteria have moved away from tender points. They rely on a widespread pain index and a symptom severity scale that includes fatigue, waking unrefreshed, cognitive complaints, and mood changes. The change did not settle every dispute, but it removed the fiction that fibromyalgia could be confirmed with a simple count.
| Feature | 1990 criteria | 2010/2016 criteria |
|---|---|---|
| Core measure | Tender-point count | Widespread pain index plus symptom severity |
| Tender points | 11 of 18 required | Not required |
| Symptoms beyond pain | Present but not scored | Scored explicitly |
| What it captures | Examiner-dependent tenderness | Patient-reported pain distribution and severity |
The symptoms that matter outside the pain
Pain is necessary but not sufficient. Fatigue is often the symptom patients rank as most disabling, followed by unrefreshing sleep and the cognitive slowing known as fibro fog. Memory lapses, word-finding trouble, difficulty concentrating, and an unexpected inability to keep up with familiar tasks can be mistaken for early dementia, which is frightening enough to drive some patients to a neurologist rather than a rheumatologist.
Other complaints are common but less universal: irritable bowel symptoms, bladder urgency, sensitivity to light or sound, restless legs, and low mood. The challenge is distinguishing fibromyalgia from conditions that mimic it. Hypothyroidism, rheumatoid arthritis, systemic lupus erythematosus, and sleep apnea can all cause similar symptoms, which is why a diagnosis is partly an act of exclusion.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases describes the core symptoms as widespread pain with fatigue and cognitive complaints, and notes that symptoms often worsen after physical or emotional stress. That observation matters because treatment targets stress and poor sleep, which can worsen fibromyalgia as much as the pain itself.
Photo by julien Tromeur on Unsplash
What the treatment evidence supports
Treatment is usually grouped under medication such as duloxetine or pregabalin, exercise, and psychological therapies. The evidence does not give one stream a decisive advantage, and the most useful plans combine at least two. That conclusion is less exciting than a single pill would be, but it has held up across systematic reviews.
Exercise is the least intuitive intervention because movement hurts. A graded approach, starting below the level that flares symptoms and increasing by small increments, generally produces better physical function and some reduction in pain. The Centers for Disease Control and Prevention recommends aerobic activity, muscle-strengthening exercise, flexibility work, and gentle movement on days when pain flares. The recommendation only helps if the pace is adjusted to the patient's tolerance, which trial protocols rarely capture.
Approved medications and their limits
Three drugs have regulatory approval for fibromyalgia in various countries: pregabalin, duloxetine, and milnacipran, the last of which is not available everywhere. Amitriptyline and cyclobenzaprine are sometimes used off-label, though the evidence for them is older and more modest. Each acts on the nervous system rather than on muscles, which is consistent with the view that fibromyalgia involves altered pain processing rather than tissue damage.
The clinical trial results are instructive for a different reason. In the best-known studies, only a minority of patients achieve a 30 percent or greater reduction in pain, and the placebo response is substantial. The drugs work for some patients, not for all, and they carry side effects: dizziness, nausea, weight gain, and cognitive dulling. The side-effect profile matters because cognitive dulling is already part of the condition for many patients.
NHS guidance on fibromyalgia sets out the same practical point: medication can reduce symptoms, but it is rarely sufficient on its own. That is less a criticism of the drugs than a description of the condition.
Cognitive behavioural therapy and other non-drug options
Cognitive behavioural therapy is not a claim that the pain is imagined. It targets the behaviours and thoughts that worsen function in long-term pain: avoidance, pacing failures, catastrophic interpretation of symptoms, and poor sleep habits. Systematic reviews find small to moderate improvements in pain, fatigue, physical function, and mood. The phrase 'small to moderate' should be read literally. It is not a cure, but it often changes what a person can do despite symptoms.
Other approaches have weaker but not absent support. Tai chi, yoga, supervised warm-water exercise, and structured stretching programs show benefit in some controlled trials, though the studies are smaller and more variable. Acupuncture and manual therapies have produced mixed results; patients sometimes feel better, but the mechanism remains unclear and the effect sizes are uneven.
What researchers think is happening
No single mechanism explains all cases. The leading model is central sensitization: the central nervous system amplifies pain signals so that ordinary touch or pressure can produce pain. Functional imaging shows altered activity in brain regions that process pain, but imaging findings do not yet diagnose the condition. Some studies have reported small-fibre nerve abnormalities in a subset of patients, which complicates the old assumption that fibromyalgia is purely central. The evidence sits between peripheral and central explanations, and the honest answer is that different patients may be experiencing different underlying problems.
Genetics contributes modest risk; family studies show clustering. Physical trauma, infection, surgery, or prolonged psychological stress often precedes the diagnosis, but many people with these exposures never develop the condition. The research points to a threshold model rather than a single cause.
Photo by julien Tromeur on Unsplash
What the evidence cannot yet say
Treatment studies are blunt instruments. Many enrol patients who meet broad criteria but differ considerably in symptom pattern, sleep quality, mood, and medication history. A trial that averages a group can hide a subgroup that benefits and another that does not. The same problem runs through much of the literature: fibromyalgia is treated as one thing, while the data increasingly suggest it may be several overlapping conditions sharing a label.
One question survives all the revisions: whether fibromyalgia is one disorder at all, or a name given to several conditions that happen to sit in the same diagnostic bin.